Biogen Inc

BIIBNASDAQ · USD
249.59USD0.00 (+1.00%)
6310

Biogen Inc (BIIB) Implied Volatility Current

BIIB's 30 day implied volatility is 60.95%, with an IV Rank of 100.00%. This is a high IV Rank versus the past year, meaning Biogen Inc options are relatively expensive and currently favor sellers. BIIB's 30 day historical volatility sits at 31.54%, which means implied volatility is running 29.41 points above historical volatility, as of Nov 20, 2026.

Read more

Tracking BIIB implied volatility helps you spot when Biogen Inc options are historically cheap or expensive, and where the best trades are hiding. When BIIB IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor BIIB implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking BIIB IV rank helps you see whether BIIB's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.

Implied Volatility

IV Rank
100.00%IV Rank
High

IV is highly elevated. Premiums are expensive, strongly favoring sellers.

Implied Volatility (30d)60.95%

IV Rank100.00%

Historical Volatility (30d)31.54%

IV Minus HV+29.41%

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →